Analysis of Long-term (Investment) Activity Ratios
Quarterly Data
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Long-term Activity Ratios (Summary)
IQVIA Holdings Inc., long-term (investment) activity ratios (quarterly data)
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | IQVIA Holdings Inc. net fixed asset turnover ratio improved from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
| Net fixed asset turnover (including operating lease, right-of-use asset) | An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). | IQVIA Holdings Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) improved from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | IQVIA Holdings Inc. total asset turnover ratio improved from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
| Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | IQVIA Holdings Inc. equity turnover ratio improved from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Net Fixed Asset Turnover
IQVIA Holdings Inc., net fixed asset turnover calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Revenues | 3,736) | 3,728) | 3,652) | 3,739) | 3,562) | 3,541) | 3,568) | 3,636) | 3,391) | 3,438) | 3,409) | 3,298) | 2,786) | 2,521) | 2,754) | 2,895) | 2,769) | 2,740) | 2,684) | 2,688) | 2,594) | 2,567) | 2,563) | |||||||
| Property and equipment, net | 498) | 510) | 520) | 532) | 507) | 529) | 531) | 497) | 485) | 470) | 472) | 482) | 452) | 444) | 445) | 458) | 451) | 458) | 437) | 434) | 417) | 415) | 432) | |||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||||||||
| Net fixed asset turnover1 | 29.83 | 28.79 | 27.87 | 27.09 | 28.22 | 26.72 | 26.43 | 27.92 | 27.91 | 27.51 | 25.45 | 23.57 | 24.24 | 24.64 | 25.07 | 24.21 | 24.13 | 23.38 | 24.10 | 23.99 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 11.18 | 11.33 | 11.51 | 11.76 | 11.82 | 11.57 | 11.18 | 11.00 | 10.75 | 10.41 | 9.67 | 8.73 | 8.15 | 7.38 | 11.50 | 11.23 | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 4.61 | 4.58 | 4.56 | 4.57 | 4.73 | 4.77 | 4.75 | 4.69 | 4.89 | 4.92 | 4.93 | 4.96 | 4.94 | 4.78 | 4.68 | 4.51 | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 6.93 | 7.11 | 7.30 | 7.38 | 7.74 | 7.90 | 7.77 | 7.67 | 7.75 | 7.66 | 7.43 | 7.22 | 6.86 | 6.03 | 5.07 | 4.18 | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 6.59 | 6.98 | 7.31 | 7.96 | 8.40 | 8.12 | 7.94 | 7.77 | 7.71 | 7.84 | 7.59 | 6.83 | 6.68 | 6.35 | 6.03 | 7.78 | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 2.70 | 2.62 | 2.63 | 2.81 | 3.14 | 3.18 | 3.22 | 3.15 | 3.11 | 3.02 | 2.95 | 2.83 | 2.80 | 2.88 | 2.92 | 2.83 | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 4.88 | 4.91 | 4.88 | 4.93 | 5.01 | 5.13 | 5.18 | 5.27 | 5.40 | 5.27 | 5.06 | 4.90 | 4.74 | 4.70 | 4.90 | 4.91 | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 4.86 | 4.56 | 4.58 | 4.79 | 5.29 | 5.21 | 5.07 | 4.95 | 4.95 | 4.79 | 4.59 | 4.40 | 4.53 | 4.57 | 4.75 | 4.65 | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 2.63 | 2.62 | 2.66 | 2.77 | 2.89 | 2.85 | 2.73 | 2.53 | 2.57 | 2.61 | 2.55 | 2.67 | 2.80 | 2.99 | 3.15 | 3.11 | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 3.84 | 4.46 | 5.45 | 6.17 | 6.47 | 6.64 | 6.12 | 5.46 | 4.79 | 3.89 | 3.31 | 3.01 | 2.98 | 3.21 | 3.47 | 3.71 | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 3.27 | 3.23 | 3.19 | 3.23 | 3.70 | 3.91 | 4.64 | 4.62 | 3.99 | 3.69 | 2.82 | 2.64 | 2.63 | 2.64 | 2.71 | 2.72 | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 4.74 | 4.68 | 4.68 | 4.84 | 5.12 | 5.02 | 4.87 | 4.71 | 5.54 | 5.83 | 5.85 | 5.45 | 5.50 | 5.37 | 5.42 | 5.38 | — | — | — | — | — | — | — | |||||||
| Zoetis Inc. | 2.71 | 2.73 | 2.78 | 2.93 | 3.05 | 3.12 | 3.17 | 3.21 | 3.26 | 3.24 | 3.15 | 3.03 | 3.12 | 3.15 | 3.21 | 3.23 | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Net fixed asset turnover
= (RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023
+ RevenuesQ4 2022)
÷ Property and equipment, net
= (3,736 + 3,728 + 3,652 + 3,739)
÷ 498 = 29.83
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | IQVIA Holdings Inc. net fixed asset turnover ratio improved from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)
IQVIA Holdings Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Revenues | 3,736) | 3,728) | 3,652) | 3,739) | 3,562) | 3,541) | 3,568) | 3,636) | 3,391) | 3,438) | 3,409) | 3,298) | 2,786) | 2,521) | 2,754) | 2,895) | 2,769) | 2,740) | 2,684) | 2,688) | 2,594) | 2,567) | 2,563) | |||||||
| Property and equipment, net | 498) | 510) | 520) | 532) | 507) | 529) | 531) | 497) | 485) | 470) | 472) | 482) | 452) | 444) | 445) | 458) | 451) | 458) | 437) | 434) | 417) | 415) | 432) | |||||||
| Operating lease right-of-use assets | 292) | 319) | 325) | 331) | 333) | 370) | 407) | 406) | 404) | 430) | 437) | 471) | 490) | 502) | 489) | 496) | 490) | 498) | 517) | —) | —) | —) | —) | |||||||
| Property and equipment, net (including operating lease, right-of-use asset) | 790) | 829) | 845) | 863) | 840) | 899) | 938) | 903) | 889) | 900) | 909) | 953) | 942) | 946) | 934) | 954) | 941) | 956) | 954) | 434) | 417) | 415) | 432) | |||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||||||||
| Net fixed asset turnover (including operating lease, right-of-use asset)1 | 18.80 | 17.71 | 17.15 | 16.70 | 17.03 | 15.72 | 14.96 | 15.36 | 15.23 | 14.37 | 13.22 | 11.92 | 11.63 | 11.56 | 11.95 | 11.62 | 11.56 | 11.20 | 11.04 | 23.99 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2 | ||||||||||||||||||||||||||||||
| Zoetis Inc. | 2.52 | 2.54 | 2.59 | 2.72 | 2.82 | 2.91 | 2.95 | 2.99 | 3.02 | 3.01 | 2.90 | 2.79 | 2.85 | 2.89 | 2.94 | 2.94 | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset)
= (RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023
+ RevenuesQ4 2022)
÷ Property and equipment, net (including operating lease, right-of-use asset)
= (3,736 + 3,728 + 3,652 + 3,739)
÷ 790 = 18.80
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover (including operating lease, right-of-use asset) | An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). | IQVIA Holdings Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) improved from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Total Asset Turnover
IQVIA Holdings Inc., total asset turnover calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Revenues | 3,736) | 3,728) | 3,652) | 3,739) | 3,562) | 3,541) | 3,568) | 3,636) | 3,391) | 3,438) | 3,409) | 3,298) | 2,786) | 2,521) | 2,754) | 2,895) | 2,769) | 2,740) | 2,684) | 2,688) | 2,594) | 2,567) | 2,563) | |||||||
| Total assets | 25,977) | 26,036) | 25,739) | 25,337) | 24,223) | 24,413) | 24,969) | 24,689) | 24,033) | 23,937) | 24,467) | 24,564) | 23,837) | 23,183) | 23,078) | 23,251) | 22,892) | 23,068) | 23,109) | 22,549) | 22,498) | 22,626) | 23,235) | |||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||||||||
| Total asset turnover1 | 0.57 | 0.56 | 0.56 | 0.57 | 0.59 | 0.58 | 0.56 | 0.56 | 0.56 | 0.54 | 0.49 | 0.46 | 0.46 | 0.47 | 0.48 | 0.48 | 0.48 | 0.46 | 0.46 | 0.46 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Total Asset Turnover, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 0.40 | 0.41 | 0.42 | 0.42 | 0.41 | 0.40 | 0.40 | 0.38 | 0.37 | 0.36 | 0.33 | 0.30 | 0.27 | 0.24 | 0.37 | 0.37 | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 0.28 | 0.28 | 0.28 | 0.38 | 0.38 | 0.41 | 0.41 | 0.40 | 0.37 | 0.40 | 0.38 | 0.39 | 0.37 | 0.36 | 0.37 | 0.37 | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 0.49 | 0.48 | 0.49 | 0.48 | 0.48 | 0.47 | 0.46 | 0.42 | 0.41 | 0.40 | 0.38 | 0.36 | 0.31 | 0.27 | 0.24 | 0.20 | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 0.32 | 0.34 | 0.35 | 0.37 | 0.39 | 0.38 | 0.36 | 0.35 | 0.34 | 0.34 | 0.33 | 0.29 | 0.28 | 0.27 | 0.26 | 0.29 | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 0.55 | 0.54 | 0.52 | 0.58 | 0.62 | 0.62 | 0.62 | 0.58 | 0.58 | 0.56 | 0.54 | 0.53 | 0.53 | 0.55 | 0.56 | 0.57 | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 0.44 | 0.44 | 0.43 | 0.43 | 0.43 | 0.43 | 0.43 | 0.40 | 0.41 | 0.39 | 0.37 | 0.36 | 0.37 | 0.39 | 0.37 | 0.36 | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 0.55 | 0.49 | 0.47 | 0.51 | 0.55 | 0.54 | 0.53 | 0.52 | 0.51 | 0.51 | 0.49 | 0.47 | 0.47 | 0.51 | 0.53 | 0.52 | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 0.56 | 0.56 | 0.54 | 0.54 | 0.55 | 0.53 | 0.51 | 0.46 | 0.51 | 0.52 | 0.51 | 0.52 | 0.53 | 0.52 | 0.57 | 0.55 | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 0.32 | 0.35 | 0.48 | 0.51 | 0.51 | 0.52 | 0.50 | 0.45 | 0.39 | 0.33 | 0.29 | 0.27 | 0.24 | 0.25 | 0.29 | 0.31 | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 0.41 | 0.41 | 0.41 | 0.42 | 0.50 | 0.52 | 0.63 | 0.63 | 0.57 | 0.58 | 0.52 | 0.50 | 0.51 | 0.55 | 0.51 | 0.53 | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 0.45 | 0.46 | 0.46 | 0.46 | 0.49 | 0.47 | 0.44 | 0.41 | 0.53 | 0.57 | 0.54 | 0.47 | 0.44 | 0.43 | 0.44 | 0.44 | — | — | — | — | — | — | — | |||||||
| Zoetis Inc. | 0.59 | 0.60 | 0.59 | 0.54 | 0.59 | 0.58 | 0.57 | 0.56 | 0.56 | 0.53 | 0.51 | 0.49 | 0.48 | 0.49 | 0.55 | 0.54 | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Total asset turnover
= (RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023
+ RevenuesQ4 2022)
÷ Total assets
= (3,736 + 3,728 + 3,652 + 3,739)
÷ 25,977 = 0.57
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | IQVIA Holdings Inc. total asset turnover ratio improved from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Equity Turnover
IQVIA Holdings Inc., equity turnover calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Revenues | 3,736) | 3,728) | 3,652) | 3,739) | 3,562) | 3,541) | 3,568) | 3,636) | 3,391) | 3,438) | 3,409) | 3,298) | 2,786) | 2,521) | 2,754) | 2,895) | 2,769) | 2,740) | 2,684) | 2,688) | 2,594) | 2,567) | 2,563) | |||||||
| Equity attributable to IQVIA Holdings Inc.’s stockholders | 5,805) | 5,748) | 5,932) | 5,765) | 5,347) | 5,352) | 5,919) | 6,042) | 5,829) | 5,760) | 5,953) | 6,001) | 5,846) | 5,591) | 5,542) | 6,003) | 6,131) | 6,523) | 6,615) | 6,714) | 7,215) | 7,364) | 8,196) | |||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||||||||
| Equity turnover1 | 2.56 | 2.55 | 2.44 | 2.50 | 2.68 | 2.64 | 2.37 | 2.30 | 2.32 | 2.24 | 2.02 | 1.89 | 1.87 | 1.96 | 2.01 | 1.85 | 1.77 | 1.64 | 1.59 | 1.55 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Equity Turnover, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 4.56 | 4.35 | 4.27 | 3.36 | 3.62 | 3.91 | 3.48 | 3.65 | 4.07 | 4.27 | 3.66 | 3.50 | 2.66 | 2.46 | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 3.35 | 3.73 | 4.66 | 6.77 | 6.71 | 10.17 | 26.68 | 3.63 | 2.96 | 2.93 | 2.56 | 2.58 | 2.17 | 2.17 | 2.41 | 2.30 | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 1.55 | 1.41 | 1.44 | 1.49 | 1.43 | 1.45 | 1.49 | 1.29 | 1.22 | 1.21 | 1.14 | 1.12 | 0.79 | 0.71 | 0.62 | 0.51 | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 0.54 | 0.56 | 0.58 | 0.63 | 0.67 | 0.66 | 0.65 | 0.65 | 0.65 | 0.62 | 0.61 | 0.56 | 0.54 | 0.52 | 0.58 | 0.59 | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 2.86 | 2.67 | 2.47 | 2.68 | 2.90 | 3.40 | 3.14 | 3.15 | 3.58 | 4.15 | 3.69 | 4.35 | 4.81 | 5.61 | 7.50 | 8.56 | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 1.22 | 1.28 | 1.27 | 1.27 | 1.27 | 1.34 | 1.37 | 1.28 | 1.27 | 1.34 | 1.33 | 1.34 | 1.31 | 1.21 | 1.01 | 0.98 | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 1.28 | 1.25 | 1.30 | 1.24 | 1.29 | 1.25 | 1.27 | 1.27 | 1.30 | 1.28 | 1.28 | 1.31 | 1.25 | 1.28 | 1.35 | 1.38 | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 1.44 | 1.51 | 1.24 | 1.29 | 1.33 | 1.32 | 1.32 | 1.28 | 1.33 | 1.41 | 1.73 | 1.90 | 1.62 | 1.71 | 1.83 | 1.81 | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 0.71 | 0.79 | 0.92 | 1.05 | 1.08 | 1.16 | 1.12 | 1.05 | 0.91 | 0.79 | 0.68 | 0.66 | 0.66 | 0.70 | 0.75 | 0.82 | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 0.53 | 0.53 | 0.53 | 0.54 | 0.64 | 0.69 | 0.83 | 0.86 | 0.78 | 0.82 | 0.77 | 0.77 | 0.81 | 0.88 | 0.66 | 0.71 | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 0.96 | 0.99 | 1.04 | 1.02 | 1.01 | 1.01 | 1.00 | 0.96 | 1.01 | 1.04 | 1.02 | 0.93 | 0.90 | 0.88 | 0.90 | 0.86 | — | — | — | — | — | — | — | |||||||
| Zoetis Inc. | 1.65 | 1.78 | 1.80 | 1.83 | 1.72 | 1.75 | 1.69 | 1.71 | 1.63 | 1.70 | 1.71 | 1.77 | 1.82 | 2.13 | 2.30 | 2.31 | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Equity turnover
= (RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023
+ RevenuesQ4 2022)
÷ Equity attributable to IQVIA Holdings Inc.’s stockholders
= (3,736 + 3,728 + 3,652 + 3,739)
÷ 5,805 = 2.56
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | IQVIA Holdings Inc. equity turnover ratio improved from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |